Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML

NCT02686593 is registered in ClinicalTrials.gov with The University of Hong Kong as lead sponsor.

NCT NCT02686593
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02686593 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clofarabine, Cytarabine and Mitoxantrone (CLAM) for Relapsed or Refractory AML
Lead sponsor
The University of Hong Kong
Phase
Phase 2
Overall status
Completed
Start date
February 1, 2016
Completion date
May 1, 2018
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia